Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
| Autor: | Vijay M. Motghare, Chaitali S Bajait, Renuka L. Kadam, Prashant Tiple, Smita D Sontakke, Mrunalini Kalikar |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Hamilton Anxiety Rating Scale Amitriptyline Vilazodone Hydrochloride India Citalopram 030226 pharmacology & pharmacy Montgomery–Asberg Depression Rating Scale 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Internal medicine Vilazodone mental disorders Medicine Escitalopram Humans Pharmacology (medical) 030212 general & internal medicine Prospective Studies Adverse effect Pharmacology Depressive Disorder Major Clinical Research Article business.industry Middle Aged medicine.disease Antidepressive Agents 17-item Hamilton Depression Rating Scale Affect Treatment Outcome chemistry Tolerability antidepressants Montgomery–Åsberg Depression Rating Scale depression Major depressive disorder Female business medicine.drug |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 1998-3751 |
| Popis: | OBJECTIVES: To evaluate and compare efficacy and tolerability of Vilazodone with Escitalopram and Amitriptyline in patients of major depressive disorder(MDD). METHODS: This was a randomized, prospective, parallel-group, open label clinical study in which newly diagnosed patients of MDD were randomized to receive Tab Vilazodone 20 mg daily or Tab Escitalopram 20mg daily or Tab Amitriptyline 75mg daily for 12 weeks. Antidepressant activity was assessed by change in score from baseline to week 12 on HAMD-17 and MADRS scales while change in score on HAM-A scale was used to assess antianxiety effect. Change in scores on the three scales was also compared between the three treatment groups. Severity and causality of adverse events were assessed by the modified Hartwig & Siegel scale and Naranjo scale respectively. Data was analyzed in accordance with per protocol analysis. RESULTS: Reduction in HAMD-17 and MADRS scores was significantly more in vilazodone group compared to the other two drugs indicating that vilazodone is more efficacious antidepressant. Number of remitters were also significantly more in the vilazodone group (n=11) compared to escitalopram (n=4) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|